OmniRayn
← All repurposing reports
S2 (505(b)(2))

Mitochondrial Myopathy; Encephalopathy; Lactic Acidosis; And Stroke-Like Episodes

Known, approved drugs ranked as repurposing candidates for Mitochondrial Myopathy; Encephalopathy; Lactic Acidosis; And Stroke-Like Episodes — each scored for reversal of the disease expression signature, cytotoxicity-filtered, and prioritized by clinical maturity. Computational, pending wet-lab.

Preview. Candidate identities are shown below. The full ranking, quantified reversal scores, per-candidate mechanistic rationale, ClinicalTrials.gov whitespace detail, and structure-function intelligence are included with the dossier.

Top candidates preview

  1. 1sirolimusApproved
  2. 2rilmenidineApproved
  3. 3temozolomideApproved
  4. 4dexamethasoneApproved
  5. 5ranitidineApproved
  6. 6troglitazoneApproved
  7. 7valproic acidApproved
  8. 8fulvestrantApproved

Full dossier — 147 cytotox-screened candidates

Quantified reversal ranking · mechanistic rationale · CT.gov whitespace · S2 (505(b)(2)) regulatory framing · structure-function intelligence.

Acquire dossier — $3,950